These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52. Characterisation using microphysiometry of CRF receptor pharmacology. Smart D; Coppell A; Rossant C; Hall M; McKnight AT Eur J Pharmacol; 1999 Aug; 379(2-3):229-35. PubMed ID: 10497910 [TBL] [Abstract][Full Text] [Related]
53. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Ramsey SJ; Attkins NJ; Fish R; van der Graaf PH Br J Pharmacol; 2011 Oct; 164(3):992-1007. PubMed ID: 21449919 [TBL] [Abstract][Full Text] [Related]
54. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists. Saito T; Obitsu T; Kohno H; Sugimoto I; Matsushita T; Nishiyama T; Hirota T; Takeda H; Matsumura N; Ueno S; Kishi A; Kagamiishi Y; Nakai H; Takaoka Y Bioorg Med Chem; 2012 Jan; 20(2):1122-38. PubMed ID: 22196514 [TBL] [Abstract][Full Text] [Related]
55. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design. Ye Y; Liao Q; Wei J; Gao Q Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115 [TBL] [Abstract][Full Text] [Related]
56. Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists. Takeda K; Terauchi T; Hashizume M; Shikata K; Taguchi R; Murata-Tai K; Fujisawa M; Takahashi Y; Shin K; Ino M; Shibata H; Yonaga M Bioorg Med Chem; 2012 Nov; 20(22):6559-78. PubMed ID: 23062820 [TBL] [Abstract][Full Text] [Related]
57. Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists. Huang CQ; Wilcoxen K; McCarthy JR; Haddach M; Grigoriadis D; Chen C Bioorg Med Chem Lett; 2003 Oct; 13(19):3371-4. PubMed ID: 12951128 [TBL] [Abstract][Full Text] [Related]
59. Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist. Miller DC; Klute W; Calabrese A; Brown AD Bioorg Med Chem Lett; 2009 Nov; 19(21):6144-7. PubMed ID: 19782566 [TBL] [Abstract][Full Text] [Related]
60. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]